First-in-human study of SNA-125.

Trial Profile

First-in-human study of SNA-125.

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs CT 340 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2017 According to a Sienna Biopharmaceuticals media release, company is planning to initiate the study within the first half of 2018.
    • 20 May 2013 New trial record
    • 10 May 2013 First-in-human studies of CT 340 are expected to commence in 2013, according to a Creabilis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top